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Abstract   86 
Objectives. Breakthrough candidemia (BTC) on fluconazole was associated with non-87 
susceptible Candida spp. and increased mortality. This nationwide FUNGINOS study 88 
analyzed clinical and mycological BTC characteristics.  89 
Methods. 3-year prospective study in 567 consecutive candidemias. Species identification 90 
and susceptibility testing (CLSI) in reference laboratory. Data analysis according to STROBE 91 
criteria. 92 
Results. 43/576 (8%) BTC were studied: 37/43 (86%) on fluconazole (28 prophylaxis, 93 
median 200mg/day). 21% BTC vs. 23% non-BTC presented severe sepsis/septic shock. 94 
Overall mortality was 34% vs. 32%. BTC was associated with gastrointestinal mucositis 95 
(multivariate OR 5.25, 95%CI 2.23-12.40, p<0.001) and graft-versus-host-disease (6.25, 96 
1.00-38.87, p=0.05), immunosuppression (2.42, 1.03-5.68, p=0.043), parenteral nutrition 97 
(2.87, 1.44-5.71, p=0.003). Non-albicans Candida were isolated in 58% BTC vs. 35% non-98 
BTC (p=0.005). 63% of 16 BTC occurring after 10-day fluconazole were non-susceptible 99 
(Candida glabrata, Candida krusei, Candida norvegensis) vs. 19% of 21 BTC (C. glabrata) 100 
following shorter exposure (7.10, 1.60-31.30, p=0.007). Median fluconazole MIC was 4mg/l 101 
vs. 0.25mg/l (p<0.001). Ten-day fluconazole exposure predicted non-susceptible BTC with 102 
73% accuracy.  103 
Conclusions. Outcome of BTC and non-BTC was similar. Fluconazole non-susceptible BTC 104 
occurred in three out of four cases after prolonged low-dose prophylaxis. This implies 105 
reassessment of prophylaxis duration and rapid de-escalation of empirical therapy in BTC 106 
after short fluconazole exposure. 107 
 108 
  109 
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Introduction 110 
Candida spp. belong to the top ten bloodstream pathogens in the hospital [1, 2]. Candidemia 111 
is associated with 40-80% overall mortality, 5-70% attributable mortality, prolongation of 112 
hospital stay, and substantial hospital costs [3-6]. Azole prophylaxis in high-risk patients 113 
resulted in a decreasing incidence of candidemia in some hospitals [7]. A concomitant 114 
emergence of non-albicans Candida spp. with decreased susceptibility or intrinsic resistance 115 
to fluconazole, in particular Candida krusei and Candida glabrata, has been described. This 116 
shift has been reported in breakthrough candidemia (BTC) occurring on fluconazole [8-17]. A 117 
microbiological study in Candida isolates from BTC described a correlation between dose of 118 
fluconazole and minimal inhibitory concentration (MIC), without reporting related clinical data 119 
[18]. In BTC, guidelines recommend the empirical change to an echinocandin or liposomal 120 
amphotericin B, regardless of the duration of fluconazole exposure [19-21]. There is a need 121 
for more information on clinical and mycological characteristics of BTC and their impact on 122 
patients’ management and outcome. 123 
The objective of this nationwide prospective study from the Fungal Infection Network of 124 
Switzerland (FUNGINOS) was to characterize the patients at risk of BTC, the relationship 125 
between antifungal exposure, Candida spp. and antifungal susceptibility as well as the 126 
clinical severity and outcome of BTC. 127 
  128 
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Methods 129 
Patients.  130 
Consecutive episodes of candidemia were prospectively studied over a three-year period 131 
(2004-2006) in university (n=5) and university-affiliated centers (n=20) of the FUNGINOS 132 
network covering hospital care for 85% of the Swiss population. First episodes of candidemia 133 
were analyzed; relapsing or recurrent episodes were excluded. 134 
Patients with candidemia were prospectively identified by microbiology laboratory 135 
investigators. Clinical investigators collected data on patients’ demographics, risk factors, 136 
management, and outcome in a paper print report form. Data were centralized to the national 137 
study coordination. After queries to investigators, the final clinical reports were validated by 138 
the FUNGINOS data review committee (members listed in the section “Authors’ 139 
contributions”). 140 
BTC was defined as candidemia occurring during or up to 48 hours after stopping antifungal 141 
prophylaxis or treatment of a duration of at least three days [18]. 142 
The study has been approved by the Ethical Committee of the Lausanne University Hospital 143 
as the national coordinating center. 144 
Candida bloodstream isolates. 145 
The microbiology laboratories of the 25 centers used automated blood culture systems 146 
(BactecTM [Becton Dickinson, Sparks, Maryland, USA] or BacT/Alert® [bioMérieux, Marcy 147 
l'Etoile, France]). The Candida bloodstream isolates were centralized to the FUNGINOS 148 
mycological reference laboratory (Institute of Microbiology, Lausanne University Hospital). 149 
Candida species were identified by standard biochemical assays in a test gallery (ATB ID 32 150 
C®, bioMérieux, Marcy l'Etoile, France) [22]. In case of discordant species identification 151 
between center and reference laboratory, molecular identification was performed by PCR 152 
amplification and sequencing of the D1/D2 region of the large subunit of the 28S ribosomal 153 
RNA gene (28S rDNA). Antifungal susceptibility testing was performed by microtitre broth 154 
dilution method with the Sensititre® YeastOneTM test panel (TREK Diagnostic System, 155 
Cleveland, Ohio, USA). Minimal inhibitory concentrations (MIC) were interpreted according to 156 
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clinical breakpoints recommended by the Clinical and Laboratory Standards Institute (CLSI) 157 
[23]. Candida isolates with MIC fullfilling CLSI criteria for dose-dependent susceptibility and 158 
resistance were considered as non-susceptible.  159 
Data analysis  160 
The analysis was designed according to the guidelines from the Strengthening the Reporting 161 
of Observational Studies in Epidemiology (STROBE) statement [24]. 162 
Data were analyzed using the SPSS 17.0 statistical software package (SPSS Inc., Chicago, 163 
IL, U.S.A.). Categorical data were compared by Chi-square or Fisher’s exact test, and 164 
continuous variables by T-test or Mann-Whitney test. Uni- and multivariate logistic regression 165 
analyses were performed to assess the association of clinical variables with the occurrence 166 
of BTC. All variables with a p-value <0.2 in the univariate analysis were included in a 167 
multivariate logistic regression model using a step-wise forward likelihood ratio procedure, 168 
which implies that only variables significantly associated with BTC remained in the final 169 
multivariate model. Collinearity of variables in the final model was estimated using the 170 
variance inflation factor: a value <2 was considered as reflecting the absence of significant 171 
collinearity. Point estimates were reported as odds ratios (OR) with 95% confidence intervals 172 
(95%CI). A two-sided p-value <0.05 was considered statistically significant. 173 
 174 
  175 
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Results 176 
567 consecutive episodes of candidemia were reported. Forty-three episodes (8%) fullfilled 177 
the pre-defined criteria for breakthrough candidemia (BTC), while 524 (92%) did not (non-178 
BTC). 550 (97%) Candida blood isolates were sent to the FUNGINOS reference mycology 179 
laboratory. 180 
Among 43 BTC episodes, 37 (86%) occurred on fluconazole and 6 (14%) on another 181 
antifungal (3 voriconazole, 2 caspofungin, 1 itraconazole).  182 
Patients’ demographics and clinical characteristics in BTC and non-BTC are summarized in 183 
Table 1. Multivariate analysis identified independent associations of gastrointestinal (GI) tract 184 
mucositis, acute gastrointestinal GvHD, immunosuppressive drugs, and total parenteral 185 
nutrition with BTC.  186 
The proportions of Candida spp. in BTC vs. non-BTC are summarized in Table 2.  187 
After detection of BTC, 46% of patients were treated with fluconazole and 54% with another 188 
antifungal drug, while in non-BTC, 85% of patients received fluconazole and 15% an 189 
alternative regimen (p<0.001).  190 
Severe sepsis or septic shock was reported in 21% of BTC episodes vs. 23% of non-BTC 191 
(p=0.85). 34% of patients with BTC died vs. 32% with non-BTC (p=0.73). 192 
 193 
Thirty-seven BTC episodes occurred on fluconazole (76% prophylaxis, 24% therapy). The 194 
median duration of fluconazole exposure was 11.5 days (3-62) in prophylaxis vs. 5 days (4-195 
17) in therapy (p=0.008). The median daily dose of fluconazole prophylaxis was 200 mg (50-196 
800) and the median cumulative dose 2’900 mg (600-21’600).  197 
14/37 (38%) Candida spp. were non-susceptible to fluconazole (dose-dependent susceptible 198 
or resistant): 13/14 (93%) were isolated during fluconazole prophylaxis. The rate of 199 
fluconazole non-susceptibility increased with the duration of fluconazole exposure (Figure 1, 200 
Panel A). A fluconazole expoure during 10 days or longer occurred in 43% of BTC and 201 
predicted a fluconazole non-susceptible Candida isolate with 71% sensitivity, 74% specificity, 202 
63% positive predictive value (PPV), 82% negative predictive value (NPV), and 73% 203 
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accuracy (ROC curve Figure 1, Panel B). BTC occurring on fluconazole during more than 10 204 
days was more often caused by non-albicans Candida spp. when compared with a shorter 205 
exposure (13/16, 81% vs. 6/21, 29%; OR 10.90, 95%CI 2.25-52.20, p=0.001) (Figure 2). 206 
Among 16 BTC episodes after prolonged fluconazole exposure, 10 (63%; 5 C. glabrata, 4 C. 207 
krusei, 1 C. norvegensis) were non-susceptible, whereas among 21 after shorter exposure, 4 208 
(19%; 4 C. glabrata) were non-susceptible (OR 7.10, 95%CI 1.60-31.30; p=0.007). The 209 
median MIC of fluconazole in BTC isolates was 4 mg/l (range 0.125-128) when exposure 210 
exceeded 10 days vs. 0.25 mg/l (range 0.125-32) after shorter exposure (p<0.001).  211 
7/23 patients with fluconazole susceptible BTC died (overall mortality 30%) vs. 5/14 patients 212 
with fluconazole non-susceptible BTC (36%, p=1.00), respectively. Fluconazole was 213 
continued during more than three days in 9/14 (64%) BTC episodes due to non-susceptible 214 
isolates and switched to an appropriate antifungal regimen within three days in 5/14 (36%): 215 
overall mortality was 56% (5/9) and 0% (0/5), respectively (p=0.085).  216 
  217 
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Discussion 218 
This FUNGINOS study was designed on a large prospective sample of candidemias 219 
representing the nationwide epidemiology in Switzerland. Its unique characteristic was the 220 
integration of validated individual clinical and drug dosing data with mycological data from the 221 
national FUNGINOS reference laboratory. BTC due to non-susceptible non-albicans Candida 222 
spp. occurred in three out of four cases in hematological patients with toxic damage of the 223 
GI-tract receiving prolonged low-dose fluconazole prophylaxis. This observation from a 224 
robust clinical and mycological dataset provides a proof of principle of what has been 225 
described in previous reports focused on either clinical or mycological data. Implications of 226 
this finding for antifungal stewardship are: i) regular reassessment of the indication and 227 
duration of fluconazole prophylaxis for reducing the emergence of difficult to treat 228 
breakthrough infections requiring expensive parenteral regimens, ii) once species and 229 
antifungal susceptibility is known, de-escalation from empirical therapy for BTC in a majority 230 
of patients with short fluconazole pre-exposure. 231 
FUNGINOS observed BTC in 8% of 567 consecutive candidemias which occurred in an 232 
unselected hospital patient population from 25 hospitals. A retrospective survey of 409 233 
candidemias from 6 hospitals reported 9% of BTC [15]. The CANDIPOP investigators 234 
reported 15% of BTC among 237 candidemias in cancer patients [17]. A retrospective study 235 
in surgical patients with intra-abdominal infections reported 15% of BTC [16]. Other authors 236 
observed higher BTC proportions, up to 72% in hemato-oncological patients [10, 15, 25]. 237 
Different case-mix and prophylaxis policies explain this large variability in the incidence of 238 
BTC.  239 
In the FUNGINOS study 76% of BTC occurred on fluconazole prophylaxis, while rates in 240 
other surveys ranged 57%-100% [15][16][17]. GI-tract mucositis following cytotoxic 241 
chemotherapy, acute gastrointestinal GvHD, immunosuppression, and total parenteral 242 
nutrition were found to be independently associated with BTC [15, 17, 26-29]. Candidemia 243 
occurs in hemato-oncological patients after disruption of the intestinal mucosal barrier and 244 
invasion by Candida spp. colonizing the GI-tract [30, 31]. Fluconazole prophylaxis is 245 
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recommended in this high-risk setting, which explains the association of these conditions 246 
with BTC [32].  247 
Our study offers a proof of principle by reporting the clinical-microbiological relationship 248 
between prolonged low-dose fluconazole prophylaxis in high-risk hemato-oncological 249 
patients with toxic damage of the GI-tract and occurrence of BTC due to non-susceptible 250 
non-albicans Candida spp.. The selective pressure exerted on the endogenous flora 251 
highlights the importance of a regular reassessment of the duration of fluconazole 252 
prophylaxis for reducing the emergence of difficult to treat BTC. Other studies reported 40%-253 
48% of non-susceptible Candida spp. in BTC, without providing dosing information [15][17]. 254 
C. krusei and C. glabrata candidemia was observed in hemato-oncological patients on 255 
fluconazole prophylaxis, whose duration was not described [33-35]. A mycological report by 256 
Pfaller et al. reported an association of fluconazole exposure with non-susceptible 257 
candidemia [36]. High fluconazole MICs were observed in non-albicans Candida spp. from 258 
BTC [25, 37][38]. Other reports did not associate fluconazole prophylaxis with a shift in the 259 
Candida species: different epidemiological and clinical settings might explain these 260 
contrasting results [39-41]. A report by Clancy et al. from U.S. hospitals correlated 261 
fluconazole doses (>200 mg/d, >2000 mg cumulative) with dose-depent susceptible or 262 
resistant BTC, without related clinical data [18].  263 
Rates of severe sepsis/septic shock (around 20%) and overall mortality (around 30%) did not 264 
differ in BTC and non-BTC. Data from the literature range 10%-80% and 30-60%, 265 
respectively  [15-17, 25, 27]. Fluconazole susceptibility did not impact on mortality in BTC 266 
[32, 37]. While empirical antifungals other than fluconazole were more frequently prescribed 267 
in BTC, a trend to higher mortality was observed in patients with fluconazole non-susceptible 268 
BTC who were not promptly switched to an alternative regimen. Other authors recorded a 269 
reduced survival in patients with fluconazole-resistant BTC [4, 17, 38]. Despite variability in 270 
case-mix and clinical practices, these observations suggest that a strict application of 271 
guidelines recommending empirical switch to an alternative antifungal therapy improves 272 
outcome in BTC.The small number of BTC episodes is a limitation which might have resulted 273 
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in underpowered statistical analyses. Recent multicenter epidemiological surveys from 274 
Europe, South and North-America, analyzed similar samples sizes of BTC: the consistency 275 
of our findings with previous reports corroborates their robustness [15, 17, 29, 32, 37, 38]. 276 
Although the validity of data collected in 2004-2006 might be debated, FUNGINOS showed 277 
that Candida species distribution and antifungal susceptibility remained stable over a 20-year 278 
period ([1, 42], unpublished data). Based on this epidemiology, our analysis was designed in 279 
a unique, carefully validated, clinical and mycological dataset prospectively collected 280 
nationwide over a three-year period. In Switzerland, the increase of the use of echinocandins 281 
during the following decade was moderate, and fluconazole remains the first-line agent for 282 
antifungal prophylaxis and by far the most frequently prescribed antifungal (unpublished 283 
data). Alltogether these points support that the study findings are representative of the 284 
current epidemiology of BTC in Switzerland. 285 
In conclusion, severity and outcome of BTC and non-BTC were not different. Prolonged low-286 
dose fluconazole prophylaxis in hemato-oncological patients with toxic damage of the GI-287 
tract was associated with BTC due to azole-non susceptible non-albicans Candida spp.. This 288 
finding implies a regular reassessement of the duration of prophylaxis. Once species and 289 
MICs are known, a de-escalation from empirical antifungal therapy for BTC is possible in the 290 
majority of patients with short fluconazole pre-exposure.  291 
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Figure 1.  519 
 520 
Panel A. Duration of Fluconazole Exposure at the Time of Breakthrough Candidemia 521 
and Rate of Non-Susceptible Candida isolates.  522 
 523 
Thirty-seven episodes of breakthrough candidemia occurred during fluconazole prophylaxis 524 
or therapy.  525 
 526 
Panel B. Duration of Fluconazole Exposure at the Time of Breakthrough Candidemia 527 
as Predictor of Non-Susceptible Candida Isolates. 528 
 529 
 530 
Figure 2. 531 
 532 
Proportions of Isolated Candida spp. According to the Duration of Fluconazole 533 
Exposure at the Time of Breakthrough Candidemia (BTC). 534 
 535 
Non-albicans Candida spp. were more frequently isolated after fluconazole exposure 536 
exceeding 10 days (p=0.001).  537 
 538 
 539 
 540 
Table 1. 541 
 542 
Uni- and Multivariate Analysis of Demographic and Clinical Characteristics Associated 543 
with Breakthrough Candidemia.   544 
 545 
 546 
Table 2. 547 
 548 
Candida species distribution comparing breakthrough (BTC) and non-breakthrough 549 
candidemia (Non-BTC).  550 
 551 
 552 
 553 
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